Posted by Michael Wonder on 12 Oct 2016
EMA publishes EPAR for Cabometyx (cabozantinib maleate)
12 October 2016 - The EMA has published an EPAR for Ipsen's Cabometyx.
The European Commission approved Cabometyx on 9 September 2016 for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy.
